Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, which powerfully lowers LDL cholesterol (LDL-C). From a healthspan perspective, their primary benefit is the profound reduction in the risk of atherosclerotic cardiovascular disease (ASCVD), a leading cause of age-related mortality and morbidity. By preventing the buildup of arterial plaque, statins directly combat a central mechanism of aging-related vascular decline.
Verdict
Foundational for ASCVD prevention if LDL-C is elevated or high-risk.
HEALTHSPAN IMPACT
Foundational
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$5 - $50
Protocol
- Low-dose daily administration (e.g., Rosuvastatin 5-10mg) is often used for primary prevention.
Flags
- Requires a prescription and medical supervision.
- Common side effects include muscle pain (myalgia) and digestive issues.
- Associated with a small but statistically significant increased risk of developing type 2 diabetes.
- Interacts with grapefruit juice and certain drugs (e.g., macrolide antibiotics, azole antifungals).
- Individual response and side effect profiles vary between different statins.